The combination of BRAF and/or MEK inhibitors with anti-PD1 is a therapeutic alternative sometimes used in clinical practice in BRAF mutated or WT melanoma when no other approved therapeutic option or clinical trial is available. This evidence concerns the gene MAP2K7 and melanoma.